Alpha-1 Suite, RCSI Building, Beaumont Hospital, Dublin 9, Ireland
Charity Number CHY22304
Site Developed & Maintained by Ecom-Ireland
2021 © Copyright Alpha-1 Foundation Ireland. All rights reserved.
Alpha-1 Suite, RCSI Building, Beaumont Hospital, Dublin 9, Ireland
Charity Number CHY22304
Site Developed & Maintained by Ecom-Ireland
2021 © Copyright Alpha-1 Foundation Ireland. All rights reserved.
Presentation of Results of Inhaled Alpha-1 Trial at ATS conference, May 19
The American Thoracic Society (ATS) 2015 International Conference will take place May 15-20 in Denver Colorado. The ATS is a leading medical association dedicated to advancing lung, critical care and sleep medicine.
During the International Conference in Denver patient organisations, clinicians, scientists and industry from around the world will congregate to discuss the latest findings and latest therapies for lung, critical care and sleep medicine. Researchers, clinicians and experts in the Alpha-1 field will be attending the International Conference to present their latest research and findings.
Kamada Ltd. , a plasma-derived protein therapeutics company will host a panel discussion titled, “New Treatment Prospects for AATD Patients: Results from a Phase 2/3 Inhaled AAT Trial,” which will be led by Key Opinion Leaders who specialise in treating patients with alpha-1 antitrypsin deficiency on Tuesday May 19th at the ATS International Conference. The panel discussion will be moderated by Pnina Strauss, Vice President-Clinical Development and Intellectual Property at Kamada, who will initiate the discussion with a presentation of the full data set from the Phase 2/3 clinical study of inhaled AAT for the treatment of AATD, which will include the recently reported analyses of lung function and quality-of-life data as well as of other parameters.
Panel participants include:
· Professor Kenneth R. Chapman, MD, director, Canadian Registry for Alpha-1 Antitrypsin Deficiency Asthma and Airway Centre, Toronto Western Hospital, University of Toronto in Toronto, Canada;
· Professor Gerry McElvaney, MD, professor of medicine at RCSI, Beaumont Hospital, Dublin, Ireland;
· Professor Robert Stockley, MD, Lung Investigation Unit, Queen Elizabeth Hospital, Birmingham University, Birmingham, United Kingdom; and
· Jan Stolk, MD, Department of Pulmonology, Leiden University Medical Center, Leiden, The Netherlands and acting chairman of the Alpha 1 International Registry (AIR).
To read more on this panel discussion and Kamada click here. To read more on the ATS conference click here.
· Professor Kenneth R. Chapman, MD, director, Canadian Registry for Alpha-1 Antitrypsin Deficiency Asthma and Airway Centre, Toronto Western Hospital, University of Toronto in Toronto, Canada;
· Professor Gerry McElvaney, MD, professor of medicine at RCSI, Beaumont Hospital, Dublin, Ireland;
· Professor Robert Stockley, MD, Lung Investigation Unit, Queen Elizabeth Hospital, Birmingham University, Birmingham, United Kingdom; and
· Jan Stolk, MD, Department of Pulmonology, Leiden University Medical Center, Leiden, The Netherlands and acting chairman of the Alpha 1 International Registry (AIR). – See more at: http://www.alpha1.org/Newly-Diagnosed/More-Alpha-1-Resources/News/PgrID/1498/PageID/2/ArtMID/5952/ArticleID/6333#sthash.mIWKIpqa.dpuf
· Professor Kenneth R. Chapman, MD, director, Canadian Registry for Alpha-1 Antitrypsin Deficiency Asthma and Airway Centre, Toronto Western Hospital, University of Toronto in Toronto, Canada;
· Professor Gerry McElvaney, MD, professor of medicine at RCSI, Beaumont Hospital, Dublin, Ireland;
· Professor Robert Stockley, MD, Lung Investigation Unit, Queen Elizabeth Hospital, Birmingham University, Birmingham, United Kingdom; and
· Jan Stolk, MD, Department of Pulmonology, Leiden University Medical Center, Leiden, The Netherlands and acting chairman of the Alpha 1 International Registry (AIR). – See more at: http://www.alpha1.org/Newly-Diagnosed/More-Alpha-1-Resources/News/PgrID/1498/PageID/2/ArtMID/5952/ArticleID/6333#sthash.mIWKIpqa.dpuf
Panel participants include:
· Professor Kenneth R. Chapman, MD, director, Canadian Registry for Alpha-1 Antitrypsin Deficiency Asthma and Airway Centre, Toronto Western Hospital, University of Toronto in Toronto, Canada;
· Professor Gerry McElvaney, MD, professor of medicine at RCSI, Beaumont Hospital, Dublin, Ireland;
· Professor Robert Stockley, MD, Lung Investigation Unit, Queen Elizabeth Hospital, Birmingham University, Birmingham, United Kingdom; and
· Jan Stolk, MD, Department of Pulmonology, Leiden University Medical Center, Leiden, The Netherlands and acting chairman of the Alpha 1 International Registry (AIR). – See more at: http://www.alpha1.org/Newly-Diagnosed/More-Alpha-1-Resources/News/PgrID/1498/PageID/2/ArtMID/5952/ArticleID/6333#sthash.mIWKIpqa.dpuf
Info Centre
What is Alpha-1 Antitrypsin?
Alpha-1 antitrypsin is a vital protein produced by the liver to protect the lungs. It provides protection from the harmful effects of infections and inhaled irritants, particularly tobacco smoke. It can be easily measured by a simple blood test.
What is Alpha-1 Antitrypsin Deficiency?
Alpha-1 antitrypsin deficiency (Alpha-1) is a genetic condition which, after cystic fibrosis, is the commonest genetic disorder in Ireland. It severely affects more than 15,000 people, with another 250,000 carriers also at risk of lung and liver disease on the island of Ireland. It is a proven genetic risk factor for chronic obstructive pulmonary disease (COPD).
How Do I Get Tested?
The Alpha-1 Foundation Ireland provides free testing for Alpha-1 as part of a national screening programme which is funded by the HSE. It is a simple blood test. For more details ring 01-8093871 or email alpha1@rcsi.ie